Press Releases April 27, 2026 04:25 PM

Beta Bionics to Present at the Bank of America Securities Health Care Conference

Beta Bionics to Present at Bank of America Securities Health Care Conference

By Sofia Navarro
Share
Twitter Reddit Facebook LinkedIn
BBNX

Beta Bionics, Inc., a Nasdaq-listed medical device company specializing in advanced diabetes management solutions, announced its management will present at the upcoming Bank of America Securities Health Care Conference. The company is known for its iLet Bionic Pancreas, an FDA-cleared autonomous insulin delivery system.

Beta Bionics to Present at the Bank of America Securities Health Care Conference
BBNX
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Beta Bionics is presenting at a major healthcare securities conference, increasing visibility among investors.
  • The company focuses on advanced adaptive closed-loop algorithms for diabetes management, highlighting innovation in medical devices.
  • The iLet Bionic Pancreas is FDA-cleared and commercial-stage, signaling progress in improving diabetes treatment.

IRVINE, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that management will present at the Bank of America Securities Health Care Conference in Las Vegas on Tuesday, May 12, 2026 at 2:20 pm Eastern Time (11:20 am Pacific Time).

A live audio webcast of the presentation will be available on the Company’s website in the “Investors—Events & Presentations” section at https://investors.betabionics.com, and will be archived there for future replay following the event.

About Beta Bionics

Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development, and commercialization of innovative solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing advanced adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The iLet Bionic Pancreas is the first FDA-cleared insulin delivery device that autonomously determines every insulin dose and offers the potential to substantially improve overall outcomes across broad populations of PWD. To learn more, visit www.betabionics.com.

Investor Relations:
Blake Beber
Head of Investor Relations
[email protected]

Media and Public Relations:
Felicia Sanborn
Vice President of Marketing
[email protected]

Source: Beta Bionics, Inc.


Risks

  • Market adoption and sales success of the iLet Bionic Pancreas remain uncertain in a competitive medical device sector.
  • Regulatory and reimbursement changes could impact future commercialization efforts.
  • Technological reliability and user acceptance of autonomous insulin delivery systems entail ongoing challenges.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026